Aldeyra Therapeutics, Inc. · NASDAQ:ALDX
Aldeyra Therapeutics — Corporate Update (May 2020)
16 slides from Aldeyra Therapeutics's corporate update, May 20, 2020
Slide 1: COVID-19 Development Update
COVID-19 Development Update May 20, 2020 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020 Systems-Based Approaches for Immunological Disease Exhibit 99.1
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended
Slide 3: Two Systems-Based Approaches for Treatment of COVID-19
For the Treatment of COVID-19, Aldeyra Is Developing Two Systems-Based Approaches That Potentially Modulate Numerous Targets Aldeyra Therapeutics is developing ADX-629 and ADX-1612 as investigational new drugs for the treatment of immune mediated diseases, including cancer. Aldeyra has initiated com
Slide 4: ADX-1612: A Potential COVID-19 Antiviral with Nanomolar Potency
ADX-1612: A Potential COVID-19 Antiviral with Nanomolar Potency COVID-19 DEVELOPMENT UPDATE May 2020 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 5: ADX-1612 Potentially Synergistic with Antivirals Targeting Viral Nucleic Acids
ADX-1612 Represents a Potentially Synergistic Treatment with Antivirals that Target Viral Nucleic Acids Folded Protein Complexes RNA SARS-CoV-2 Virus ADX-1612 Remdesivir Virus Neutralization Assay: EC50 = 750 nM Virus Neutralization Assay: Virus-induced cell death blocked at 80-160 nM Remdesivir in
Slide 6: ADX-1612 Inhibits HSP90, Required for Viral Infection Processes
ADX-1612 Inhibits HSP90, Which is Required for Multiple Processes Associated with Viral Infection Wang et al. HSP90: a promising broad‑spectrum antiviral drug target. Arch Virol, August 5, 2017; DOI 10.1007/s00705-017-3511-1 HSP90 Replication Host Cell Exit Host Cell Infection HSP90 inhibitors have
Slide 7: HSP90 Identified as Potential Therapeutic Target of SARS-CoV-2
HSP90 Recently Identified as a Potential Therapeutic Target of SARS-CoV-2 Elevated HSP90 RNA found in SARS-CoV-2, and a low-potency HSP90 inhibitor reduced viral load in cell culture Emanuel et al. Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies mole
Slide 8: ADX-1612 Tested in Over 1600 Cancer Patients, Antiviral Activity Shown
ADX-1612 Has Been Tested in Over 1600 Cancer Patients to Date, and Has Clinically Demonstrated Antiviral Activity in a Viral-Induced Cancer Shatzer et al. Ganetespib, an HSP90 inhibitor, kills Epstein–Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blo
Slide 9: ADX-1612 Potential Suppression of Pathologic Inflammation
In Addition to Antiviral Activity, ADX-1612 Has Demonstrated Potential Suppression of Pathologic Inflammation 1Liu et al. The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus, PLoS
Slide 10: ADX-1612 Planned COVID-19 Clinical Trial Synopsis
ADX-1612 Planned Phase 2 COVID-19 Clinical Trial Synopsis* Patient Population: Adults and children hospitalized for COVID-19 with an oxygen saturation (SpO2) ≤ 94% on room air, or requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation Size: Up to 30 subjects, r
Slide 11: ADX-1612 Development Milestones and Clinical Plans
COVID-19 IND submission Q3 2020 Coronavirus Treatment Acceleration Program application May 2020 Expected ADX-1612 Development Milestones and Clinical Plans* Initiation of clinical testing for COVID-19 Q3 2020 Completion of enrollment for ovarian cancer (the Phase 2 EUDARIO Trial) June 2020 *The timi
Slide 12: ADX-629 For The Potential Treatment of Cytokine Release Syndrome
ADX-629 For The Potential Treatment of Cytokine Release Syndrome COVID-19 DEVELOPMENT UPDATE May 2020 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 13: ADX-629 Pre-Cytokine Systems-Based Approach to Mitigate Cytokine Responses
ADX-629 is a Pre-Cytokine, Systems-Based Approach with the Potential to Mitigate Cytokine Responses in COVID-19 RASP LPS Animal Model of Cytokine Storm ADX-629 RASP = Reactive Aldehyde Species; Cytokine data on file; LPS = lipopolysaccharide NF-KB translocation Inflammasome activation Scavenger rece
Slide 14: ADX-629 Planned COVID-19 Clinical Trial Synopsis
ADX-629 Planned Phase 2 COVID-19 Clinical Trial Synopsis* Patient Population: COVID-19 patients recently admitted to hospital for respiratory compromise Dosing: 600mg oral twice daily Size: Up to 30 subjects, randomized 2:1 drug:placebo Treatment Period: Up to 28 days Endpoints: Proportion on mechan
Slide 15: ADX-629 Development Milestones and Clinical Plans
BARDA CoronaWatch application May 2020 Coronavirus Treatment Acceleration Program (CTAP) application March 2020 Expected ADX-629 Development Milestones and Clinical Plans* BARDA CoronaWatch meeting accepted (to be scheduled) *The timing of clinical trial initiation depends, in part, on restrictions
Slide 16: Systems-Based Approaches for Immunological Disease
Systems-Based Approaches for Immunological Disease Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020